Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5070/D329461918 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tache and talon noir in patient with mycosis fungoides on acitretin.
Dermatol Online J
August 2023
The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York. Veterans Affairs New York Harbor Healthcare System, New York, New York..
Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era?
Clin Infect Dis
September 2013
INSERM U1018, Centre for Research in Epidemiology and Population Health, Université Paris-Sud, Paris, France.
Background: Intrapartum intravenous zidovudine (ZDV) prophylaxis is a long-standing component of prevention of mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) in high-resource countries. In some recent guidelines, intravenous ZDV is no longer systematically recommended for mothers receiving combination antiretroviral therapy (cART) with low viral load. We evaluated the impact of intravenous ZDV according to viral load and obstetrical conditions.
View Article and Find Full Text PDFAssociation of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.
JAMA
July 2011
Unité d’Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.
Context: Lopinavir-ritonavir is a human immunodeficiency virus 1 (HIV-1) protease inhibitor boosted by ritonavir, a cytochrome p450 inhibitor. A warning about its tolerance in premature newborns was recently released, and transient elevation of 17-hydroxyprogesterone (17OHP) was noted in 2 newborns treated with lopinavir-ritonavir in France.
Objective: To evaluate adrenal function in newborns postnatally treated with lopinavir-ritonavir.
Previous antiretroviral therapy for prevention of mother-to-child transmission of HIV does not hamper the initial response to PI-based multitherapy during subsequent pregnancy.
J Acquir Immune Defic Syndr
June 2011
CESP INSERM U1018, Equipe VIH et IST Le Kremlin-Bicêtre, France.
Background: Few data are available on the possible long-term negative effects of a short exposure to antiretroviral therapy (ART) for prevention of mother-to-child transmission (PMTCT).
Objective: To determine whether ART for PMTCT, discontinued after delivery, affects the virological response to highly active antiretroviral therapy (HAART) administered during subsequent pregnancies.
Methods: All current pregnancies of HIV-1-infected women enrolled in the French Perinatal Cohort (ANRS CO-01 EPF) between 2005 and 2009 and not receiving ART at the time of conception were eligible.
Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1.
Clin Infect Dis
October 2010
Virology Laboratory, Hospital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France.
Background: Management of pregnant women with human immunodeficiency virus (HIV) type 2 infection remains unclear because of its low prevalence and important differences from HIV-1.
Methods: Pregnant women monoinfected with HIV-2 or HIV-1 and their infants enrolled in the prospective, national, multicenter French Perinatal Cohort between 1986 and 2007.
Results: Overall, 2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!